Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCohney, Solomon (Shlomo)-
dc.contributor.otherSnell, Greg-
dc.contributor.otherHolmes, M.-
dc.contributor.otherLevvey, Bronwyn-
dc.contributor.otherShipp, A.-
dc.contributor.otherRobertson, C.-
dc.contributor.otherWestall, G. P.-
dc.identifier.citationAm J Transplant. 2013 May;13(5):1350-3.en_US
dc.description.abstractWith ABO blood group incompatibility (ABOi) between donor and recipient becoming a part of mainstream living-donor renal transplantation, the applicability of ABOi to other areas of transplantation is being reconsidered. Here we present a case of inadvertent ABOi lung retransplantation managed successfully with initial plasmapheresis, antithymocyte globulin and intravenous immunoglobulin; and subsequently with oral cyclophosphamide and sirolimus in addition to tacrolimus and prednisolone. Interestingly, in the setting of solid levels of tacrolimus and sirolimus, the patient developed a fatal thrombotic microangiopathy of uncertain origin subsequent to the cessation of cyclophosphamide at 9 years posttransplant. It is apparent that ABOi lung transplantation can result in surprisingly successful long-term outcomes. Low pretransplant antibody titers likely aid this and, in pediatric neonatal or infant cases, this may not be uncommon. We must proceed cautiously as there are significant risks. Understanding the monitoring, prevention and treatment of lung transplant antibody-mediated rejection, while avoiding the long-term complications of overimmunosuppression, will be the keys to the success of future cases.en_US
dc.publisherWiley Onlineen_US
dc.subjectABO Blood-Group Systemen_US
dc.subjectBlood Group Incompatibilityen_US
dc.subjectBlood Group Incompatibilityen_US
dc.subjectFatal Outcomeen_US
dc.subjectGraft Rejectionen_US
dc.subjectLung Transplantationen_US
dc.subjectABO Blood-Group Systemen_US
dc.subjectAntithymocyte globulinen_US
dc.subjectIntravenous Immunoglobulinen_US
dc.subjectOral Cyclophosphamideen_US
dc.subjectFatal Thrombotic Microangiopathyen_US
dc.subjectPretransplant Antibody Titersen_US
dc.subjectUroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.subjectDepartment of Gastroenterology, Epworth HealthCare, Victoria, Australiaen_US
dc.titleLessons and insights from ABO incompatible lung transplantation.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAmerican Journal of Transplantationen_US
dc.description.affiliatesDepartment of Allergy, Immunology and Respiratory Medicine, Lung Transplant Service, Alfred Hospital and Monash University, Melbourne, Australia.en_US
dc.type.studyortrialCase Reportsen_US
Appears in Collections:UroRenal, Vascular

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.